-
Something wrong with this record ?
New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases
A. Tichy, J. Marek, R. Havelek, J. Pejchal, M. Seifrtova, L. Zarybnicka, A. Filipova, M. Rezacova, Z. Sinkorova,
Current drug targets.
2018 ;
19 (16) :
1943-1957.
[pub] -
Language English Country United Arab Emirates
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Persistent link
https://www.medvik.cz/link/bmc19045504
- MeSH
- Apoptosis drug effects genetics MeSH
- Molecular Targeted Therapy methods MeSH
- Cardiovascular Agents pharmacology therapeutic use MeSH
- Cardiovascular Diseases drug therapy pathology MeSH
- Humans MeSH
- Tumor Suppressor Protein p53 antagonists & inhibitors genetics metabolism MeSH
- Neoplasms genetics radiotherapy MeSH
- Neurodegenerative Diseases drug therapy pathology MeSH
- Neuroprotective Agents pharmacology therapeutic use MeSH
- DNA Damage drug effects radiation effects MeSH
- Apoptosis Regulatory Proteins antagonists & inhibitors metabolism MeSH
- Proto-Oncogene Proteins antagonists & inhibitors metabolism MeSH
- Radiation Injuries prevention & control MeSH
- Radiation-Protective Agents pharmacology therapeutic use MeSH
- Signal Transduction drug effects genetics MeSH
- Radiation Tolerance drug effects MeSH
- Protein Binding drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045504
- 003
- CZ-PrNML
- 005
- 20200113143350.0
- 007
- ta
- 008
- 200109s2018 ts f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1389450119666180406110743 $2 doi
- 035 __
- $a (PubMed)29623837
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ts
- 100 1_
- $a Tichy, Ales $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence in Brno, 500 01 Hradec Kralove, Czech Republic. Biomedical Research Center, University Hospital, 500 05 Hradec Kralove, Czech Republic.
- 245 10
- $a New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases / $c A. Tichy, J. Marek, R. Havelek, J. Pejchal, M. Seifrtova, L. Zarybnicka, A. Filipova, M. Rezacova, Z. Sinkorova,
- 520 9_
- $a This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
- 650 _2
- $a apoptóza $x účinky léků $x genetika $7 D017209
- 650 _2
- $a proteiny regulující apoptózu $x antagonisté a inhibitory $x metabolismus $7 D051017
- 650 _2
- $a kardiovaskulární látky $x farmakologie $x terapeutické užití $7 D002317
- 650 _2
- $a kardiovaskulární nemoci $x farmakoterapie $x patologie $7 D002318
- 650 _2
- $a poškození DNA $x účinky léků $x účinky záření $7 D004249
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a cílená molekulární terapie $x metody $7 D058990
- 650 _2
- $a nádory $x genetika $x radioterapie $7 D009369
- 650 _2
- $a neurodegenerativní nemoci $x farmakoterapie $x patologie $7 D019636
- 650 _2
- $a neuroprotektivní látky $x farmakologie $x terapeutické užití $7 D018696
- 650 _2
- $a vazba proteinů $x účinky léků $7 D011485
- 650 _2
- $a protoonkogenní proteiny $x antagonisté a inhibitory $x metabolismus $7 D011518
- 650 _2
- $a radiační poranění $x prevence a kontrola $7 D011832
- 650 _2
- $a tolerance záření $x účinky léků $7 D011836
- 650 _2
- $a radioprotektivní látky $x farmakologie $x terapeutické užití $7 D011837
- 650 _2
- $a signální transdukce $x účinky léků $x genetika $7 D015398
- 650 _2
- $a nádorový supresorový protein p53 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Marek, Jan $u Biomedical Research Center, University Hospital, 500 05 Hradec Kralove, Czech Republic.
- 700 1_
- $a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic.
- 700 1_
- $a Pejchal, Jaroslav $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence in Brno, 500 01 Hradec Kralove, Czech Republic.
- 700 1_
- $a Seifrtova, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic.
- 700 1_
- $a Zarybnicka, Lenka $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence in Brno, 500 01 Hradec Kralove, Czech Republic.
- 700 1_
- $a Filipova, Alzbeta $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence in Brno, 500 01 Hradec Kralove, Czech Republic.
- 700 1_
- $a Rezacova, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic.
- 700 1_
- $a Sinkorova, Zuzana $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defence in Brno, 500 01 Hradec Kralove, Czech Republic.
- 773 0_
- $w MED00007902 $t Current drug targets $x 1873-5592 $g Roč. 19, č. 16 (2018), s. 1943-1957
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29623837 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113143722 $b ABA008
- 999 __
- $a ok $b bmc $g 1483772 $s 1084177
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 19 $c 16 $d 1943-1957 $e - $i 1873-5592 $m Current drug targets $n Curr Drug Targets $x MED00007902
- LZP __
- $a Pubmed-20200109
